BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+11.22%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$10.3B
AUM Growth
+$10.3B
(+14%)
Cap. Flow
+$826M
Cap. Flow
% of AUM
8.01%
Top 10 Holdings %
Top 10 Hldgs %
81.62%
Holding
101
New
12
Increased
23
Reduced
8
Closed
11
Top Buys
| 1 |
Insmed
INSM
|
$235M |
| 2 |
Summit Therapeutics
SMMT
|
$198M |
| 3 |
Alkermes
ALKS
|
$55.1M |
| 4 |
Revolution Medicines
RVMD
|
$52.5M |
| 5 |
Structure Therapeutics
GPCR
|
$44.5M |
Top Sells
| 1 |
CRISPR Therapeutics
CRSP
|
$22.3M |
| 2 |
argenx
ARGX
|
$22M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$17.6M |
| 4 |
TSVT
2seventy bio
TSVT
|
$12.3M |
| 5 |
Akero Therapeutics
AKRO
|
$12M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Cidara Therapeutics
CDTX
$1.66B
| $11.1M | 0.11% | +227,272 | New | +$11.1M |
|
52
Arcellx
ACLX
$3.85B
| $11M | 0.11% | +166,825 | New | +$11M |
|
53
Nuvalent
NUVL
$5.52B
| $11M | 0.11% | +143,937 | New | +$11M |
|
54
Spyre Therapeutics
SYRE
$996M
| $9.38M | 0.09% | +626,703 | New | +$9.38M |
|
55
Taysha Gene Therapies
TSHA
$797M
| $9.25M | 0.09% | 4,004,756 | – | – |
|
56
Prelude Therapeutics
PRLD
$68.5M
| $8.19M | 0.08% | 10,123,824 | – | – |
|
57
Crinetics Pharmaceuticals
CRNX
$2.92B
| $8.05M | 0.08% | +280,000 | New | +$8.05M |
|
58
CytomX Therapeutics
CTMX
$336M
| $7.91M | 0.08% | +3,484,226 | New | +$7.91M |
|
59
Sagimet Biosciences
SGMT
$244M
| $7.26M | 0.07% | 952,996 | – | – |
|
|
SION
60
Sionna Therapeutics, Inc. Common Stock
SION
$1.09B
| $6.94M | 0.07% | 400,000 | – | – |
|
61
Agios Pharmaceuticals
AGIO
$2.19B
| $6.31M | 0.06% | +189,866 | New | +$6.31M |
|
|
RAPP
62
Rapport Therapeutics
RAPP
$643M
| $6.25M | 0.06% | +550,090 | New | +$6.25M |
|
63
Skye Bioscience
SKYE
$108M
| $6.06M | 0.06% | 1,450,638 | – | – |
|
64
Design Therapeutics
DSGN
$315M
| $5.77M | 0.06% | 1,712,882 -30,843 | -2% | -$104K |
|
65
KALA BIO
KALA
$78.8M
| $5.72M | 0.06% | 1,201,894 | – | – |
|
66
Sana Biotechnology
SANA
$777M
| $5.54M | 0.05% | 2,030,949 | – | – |
|
67
Xencor
XNCR
$580M
| $5.27M | 0.05% | 670,431 | – | – |
|
|
ALMS
68
Alumis Inc. Common Stock
ALMS
$479M
| $4.69M | 0.05% | 1,562,500 | – | – |
|
|
IGMS
69
DELISTED
IGM Biosciences
IGMS
| $4.59M | 0.04% | 4,096,210 +953 | +0% | +$1.07K |
|
70
TScan Therapeutics
TCRX
$102M
| $4.04M | 0.04% | 2,784,792 | – | – |
|
71
Relay Therapeutics
RLAY
$619M
| $4.01M | 0.04% | 1,160,117 | – | – |
|
72
Fate Therapeutics
FATE
$120M
| $2.78M | 0.03% | 2,485,018 -773,384 | -24% | -$866K |
|
73
Vir Biotechnology
VIR
$686M
| $2.73M | 0.03% | 542,539 | – | – |
|
74
Enliven Therapeutics
ELVN
$1.2B
| $2.3M | 0.02% | 114,833 | – | – |
|
75
Wave Life Sciences
WVE
$1.53B
| $2.24M | 0.02% | 344,063 | – | – |
|